13F Filings History of DEERFIELD MANAGEMENT COMPANY, L.P.

Latest 13F report
Q4 2025 - 17 Feb 2026
Value $
$7,800,675,970
Signature - Title
Deerfield UGP, LLC, its general partner - Chief Financial Officer
Location
New York, NY
Summary
This page shows a list of all the recent 13F filings made by DEERFIELD MANAGEMENT COMPANY, L.P.. Form 13F is required to be filed within 45 days of the end of a calendar quarter. DEERFIELD MANAGEMENT COMPANY, L.P. reported 149 stock holdings with total value $7,800,675,970 as of Q4 2025. Top holdings included NUVL, BROOKDALE SR LIVING INC, COGT, PRAX, and CNC.

Notify me when DEERFIELD MANAGEMENT COMPANY, L.P. files a new 13F portfolio report.

⭐ Subscribe ⭐
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Filing Time
Q4 2025 149 $7,800,675,970 +$1,272,428,110 -$1,441,130,682 -$168,702,572 NUVL, BROOKDALE SR LIVING INC, COGT, PRAX, CNC 13F-HR 17 Feb 2026, 16:00
Q3 2025 151 $6,524,910,151 +$1,431,112,586 -$1,182,830,675 +$248,281,911 NUVL, CNC, MRUS, VTRS, UTHR 13F-HR 14 Nov 2025, 16:14
Q2 2025 124 $5,509,809,264 +$648,867,385 -$546,431,211 +$102,436,174 NUVL, OSCR, VTRS, MRUS, CNC 13F-HR 14 Aug 2025, 16:00
Q1 2025 122 $5,044,323,594 +$657,761,807 -$493,661,307 +$164,100,500 NUVL, VTRS, INTEGRA LIFESCIENCES HLDGS C, NBIX, CNC 13F-HR 15 May 2025, 16:00
Q4 2024 105 $5,256,971,191 +$519,836,670 -$1,117,085,439 -$597,248,769 NUVL, VTRS, INTEGRA LIFESCIENCES HLDGS C, CNC, OSCR 13F-HR 14 Feb 2025, 16:00
Q3 2024 443 $6,692,805,831 +$890,438,075 -$1,137,255,649 -$246,817,574 NUVL, VTRS, CNC, MRUS, OSCR 13F-HR 14 Nov 2024, 16:01
Q2 2024 433 $6,010,510,629 +$1,121,434,751 -$578,234,911 +$543,199,840 NUVL, INSMED INC, VTRS, CNC, INTEGRA LIFESCIENCES HLDGS C 13F-HR 14 Aug 2024, 16:30
Q1 2024 367 $5,748,069,894 +$888,564,956 -$1,209,207,623 -$320,642,667 NUVL, VTRS, CNC, LRMR, BROOKDALE SR LIVING INC 13F-HR 15 May 2024, 16:00
Q4 2023 222 $5,415,388,759 +$582,631,629 -$688,479,617 -$105,847,988 NUVL, GLAUKOS CORP, VTRS, INVITAE CORP, NATERA INC 13F-HR 14 Feb 2024, 16:01
Q3 2023 88 $4,538,793,245 +$651,436,930 -$732,582,258 -$81,145,328 NUVL, GLAUKOS CORP, VTRS, INVITAE CORP, TABULA RASA HEALTHCARE INC 13F-HR 14 Nov 2023, 16:01
Q2 2023 101 $4,684,196,241 +$468,097,591 -$720,495,120 -$252,397,529 NUVL, GLAUKOS CORP, VTRS, AMED, NATERA INC 13F-HR 14 Aug 2023, 16:23
Q1 2023 106 $4,485,670,170 +$727,468,127 -$906,503,259 -$179,035,132 NUVL, GLAUKOS CORP, NBIX, CPRX, NATERA INC 13F-HR 15 May 2023, 16:00
Q4 2022 104 $4,830,657,687 +$1,030,841,459 -$1,351,472,035 -$320,630,576 NUVL, GLAUKOS CORP, INVITAE CORP, NBIX, SAREPTA THERAPEUTICS INC 13F-HR 14 Feb 2023, 16:11
Q3 2022 126 $5,005,755,000 +$932,016,647 -$1,157,105,364 -$225,088,717 NUVL, GLAUKOS CORP, AERIE PHARMACEUTICALS INC, INVITAE CORP, NBIX 13F-HR 14 Nov 2022, 16:27
Q2 2022 123 $4,746,335,000 +$1,030,910,508 -$307,222,464 +$723,688,044 GLAUKOS CORP, NUVL, VTRS, AHCO, NBIX 13F-HR 15 Aug 2022, 16:53
Q1 2022 118 $4,437,086,000 +$743,632,475 -$485,590,628 +$258,041,847 GLAUKOS CORP, NUVL, VTRS, AHCO, INVITAE CORP 13F-HR 16 May 2022, 16:50
Q4 2021 125 $4,748,699,000 +$799,266,793 -$636,183,302 +$163,083,491 NUVL, VTRS, AHCO, GLAUKOS CORP, INVITAE CORP 13F-HR 14 Feb 2022, 17:06
Q3 2021 132 $5,112,496,000 +$1,090,103,228 -$960,552,403 +$129,550,825 NUVL, VTRS, INVITAE CORP, AHCO, CMAX 13F-HR 15 Nov 2021, 16:53
Q2 2021 143 $5,629,668,000 +$2,135,949,945 -$1,107,514,488 +$1,028,435,457 VTRS, OMIC, INVITAE CORP, CMAX, AHCO 13F-HR 16 Aug 2021, 16:27
Q1 2021 133 $4,758,345,000 +$2,336,735,785 -$2,253,586,257 +$83,149,528 INVITAE CORP, VTRS, NEVRO CORP, AERIE PHARMACEUTICALS INC, BRIDGEBIO PHARMA INC 13F-HR 17 May 2021, 16:26
Q4 2020 129 $5,059,782,000 +$2,585,664,753 -$2,253,157,321 +$332,507,432 VTRS, INVITAE CORP, NEVRO CORP, NUVASIVE INC, GRAY 13F-HR 16 Feb 2021, 16:23
Q3 2020 105 $4,106,901,000 +$1,684,626,216 -$1,259,607,400 +$425,018,816 INVITAE CORP, MYL, IMMU, NEVRO CORP, HZNP Restatement 30 Dec 2020, 16:23
Q2 2020 93 $3,433,887,000 +$872,232,665 -$1,465,607,567 -$593,374,902 HORIZON PHARMA INVT LTD, MYL, NEVRO CORP, SDGR, DFPHU 13F-HR 14 Aug 2020, 16:39
Q1 2020 90 $3,143,140,000 +$1,130,158,006 -$623,107,464 +$507,050,542 AHCO, MYL, HZNP, HORIZON PHARMA INVT LTD, NEVRO CORP 13F-HR 15 May 2020, 16:13
Q4 2019 75 $3,131,706,000 +$690,674,148 -$671,280,895 +$19,393,253 HORIZON PHARMA INVT LTD, AHCO, HZNP, MYL, NEVRO CORP 13F-HR 14 Feb 2020, 16:03
Q3 2019 94 $2,447,802,000 +$326,488,796 -$416,889,536 -$90,400,740 HZNP, HORIZON PHARMA INVT LTD, MYL, NEVRO CORP, ORTX 13F-HR 14 Nov 2019, 16:05
Q2 2019 96 $2,780,311,000 +$832,052,013 -$510,892,702 +$321,159,311 HZNP, HORIZON PHARMA INVT LTD, MYL, ORTX, NEVRO CORP 13F-HR 14 Aug 2019, 16:06
Q1 2019 93 $2,607,815,000 +$312,968,806 -$544,397,819 -$231,429,013 HZNP, FIXX, ORTX, HORIZON PHARMA INVT LTD, NEVRO CORP 13F-HR 15 May 2019, 16:31
Q4 2018 98 $2,461,050,000 +$570,312,624 -$460,044,430 +$110,268,194 HZNP, ORTX, FIXX, HORIZON PHARMA INVT LTD, NEVRO CORP 13F-HR 14 Feb 2019, 16:05
Q3 2018 102 $2,747,044,000 +$634,034,013 -$923,398,518 -$289,364,505 HZNP, FIXX, HORIZON PHARMA INVT LTD, NEVRO CORP, AERI 13F-HR 14 Nov 2018, 16:15
Q2 2018 113 $2,811,148,000 +$521,566,713 -$723,514,430 -$201,947,717 MNKKQ, HZNP, FIXX, HORIZON PHARMA INVT LTD, MRTX 13F-HR 14 Aug 2018, 16:30
Q1 2018 115 $2,818,382,000 +$797,798,198 -$539,917,258 +$257,880,940 MNKKQ, MYL, FIXX, HZNP, AVXS 13F-HR 15 May 2018, 16:31
Q4 2017 97 $2,534,140,000 +$653,814,926 -$453,094,563 +$200,720,363 MNKKQ, MYL, HZNP, DXCM, GKOS 13F-HR 14 Feb 2018, 16:20
Q3 2017 90 $2,213,322,000 +$671,806,972 -$395,654,161 +$276,152,811 AVXS, MCK, MYL, HZNP, GKOS 13F-HR 13 Nov 2017, 11:38
Q2 2017 82 $1,809,812,000 +$231,730,436 -$1,019,182,464 -$787,452,028 AVXS, HZNP, NXTM, GILD, HORIZON PHARMA INVT LTD 13F-HR 14 Aug 2017, 16:02
Q1 2017 105 $2,575,295,000 +$529,296,837 -$689,223,871 -$159,927,034 AVXS, HZNP, NXTM, HORIZON PHARMA INVT LTD, GILD 13F-HR 15 May 2017, 16:03
Q4 2016 101 $2,413,120,000 +$646,863,700 -$217,334,636 +$429,529,064 HZNP, NXTM, AVXS, PTLA, GWPH 13F-HR 14 Feb 2017, 17:03
Q3 2016 90 $2,150,130,000 +$232,173,054 -$976,028,572 -$743,855,518 GWPH, PTLA, HZNP, NXTM, AVXS 13F-HR 14 Nov 2016, 16:29
Q2 2016 106 $2,544,485,000 +$500,191,595 -$460,902,441 +$39,289,154 HZNP, NXTM, GWPH, PTLA, AVXS 13F-HR 15 Aug 2016, 10:22
Q1 2016 105 $2,332,598,000 +$745,864,184 -$404,917,021 +$340,947,163 HZNP, MYL, NXTM, HEALTHWAYS INC, HORIZON PHARMA INVT LTD 13F-HR 16 May 2016, 16:05
Q4 2015 107 $2,377,446,000 +$370,034,863 -$685,984,021 -$315,949,158 HZNP, NXTM, DYAX, ADPTQ, GSK 13F-HR 16 Feb 2016, 16:01
Q3 2015 133 $2,554,080,000 +$594,082,519 -$435,220,911 +$158,861,608 HZNP, ALLSCRIPTS HEALTHCARE SOLUTN, NXTM, GSK, AET 13F-HR 16 Nov 2015, 16:02
Q2 2015 119 $2,986,705,000 +$842,822,183 -$1,127,000,149 -$284,177,966 HZNP, ALLSCRIPTS HEALTHCARE SOLUTN, FLML, NXTM, ARRY 13F-HR 14 Aug 2015, 16:18
Q1 2015 1 $1,044,000 $0 $0 $0 CORSICANTO LTD New Holdings 14 Aug 2015, 16:16
Q1 2015 121 $3,055,579,000 +$963,560,002 -$979,547,056 -$15,987,054 ASPX, HZNP, ALLSCRIPTS HEALTHCARE SOLUTN, ABBV, NXTM 13F-HR 15 May 2015, 16:02
Q4 2014 106 $2,678,116,000 +$629,621,749 -$922,252,815 -$292,631,066 AUXL, ASPX, HZNP, AGN, FLML 13F-HR 17 Feb 2015, 16:31
Q3 2014 121 $2,463,825,000 +$764,719,893 -$481,374,176 +$283,345,717 AUXL, DENDREON CORP, AGN, NXTM, FLML 13F-HR 14 Nov 2014, 16:33
Q2 2014 117 $2,245,815,000 +$679,829,137 -$686,924,950 -$7,095,813 DENDREON CORP, AUXL, ITMN, FLML, AGN 13F-HR 14 Aug 2014, 16:33
Q1 2014 115 $2,178,289,000 +$832,295,572 -$620,818,372 +$211,477,200 DENDREON CORP, FLML, AUXL, LH, DRNA 13F-HR 15 May 2014, 16:31
Q4 2013 98 $1,773,581,000 $0 $0 $0 DENDREON CORP, AUXL, QCOR, VOLCANO CORPORATION, ARRY 13F-HR 14 Feb 2014, 16:25